Actinium Pharmaceuticals Inc., of New York, said it closed its public offering of 76.9 million common shares or common stock equivalents in lieu thereof at 32.5 cents apiece for gross proceeds of approximately $25 million. Net proceeds will be used to complete the company’s ongoing pivotal phase III Sierra trial of lead candidate Iomab-B (iodine [131I] apamistamab) in acute myelogenous leukemia, to prepare and submit a BLA to the FDA and MAA to the EMA for the CD45 antagonist and to begin pre-commercialization activities for Iomab-B in the U.S. Proceeds also will fund phase I trials of the company’s refocused CD33 program to proof of concept and support its Awe technology platform, Iomab-Act program and other R&D efforts.
Akouos Inc., of Boston, which launched in 2016 and develops gene therapies for inner ear disorders, has established terms for its IPO and plans to raise $125 million by offering 8.3 million shares at a price range of $14 to $16. The company is developing lead candidate AK-OTOF, a gene therapy focused on restoring hearing in individuals with sensorineural hearing loss due to mutations in the otoferlin gene. Without functional otoferlin protein, auditory signals received by the ear cannot be transmitted to the brain. AK-OTOF uses an adeno-associated viral vector to deliver a healthy copy of the OTOF gene to cochlear hair cells, with the goal of restoring long-term physiologic hearing following a single administration to the inner ear. The company, which raised $105 million from an oversubscribed series B round in March, plans to list its shares on Nasdaq under the ticker AKUS.
Athenex Inc., of Buffalo, N.Y., said it signed a $225 million loan agreement with funds managed by Oaktree Capital Management and expects the proceeds will be used to fund the commercial launch of oral paclitaxel and encequidar, ongoing pipeline development, refinancing of existing indebtedness, manufacturing infrastructure, and working capital and general corporate purposes. The company will receive $100 million up front, with a portion of the up-front loan proceeds being used to repay in full the existing debt facility with the Perceptive Credit Opportunities Fund. Additional debt tranches of $125 million in aggregate are subject to Athenex’s achievement of certain regulatory and commercial milestones.
Aveo Oncology Inc., of Boston, said it closed its underwritten public offering of 9.72 million shares, which includes the partial exercise by the underwriters of their option to purchase an additional 1.22 million shares, at $5.25 each for aggregate gross proceeds of $51.1 million. The net proceeds of the offering are expected to be used for working capital and general corporate purposes.
Evergreen Theragnostics Inc., of Jersey City, N.J., a radiopharmaceutical contract development and manufacturing organization, said it raised $19 million in a series A financing round. The funds will primarily be used for construction of a state-of-the-art radiopharmaceutical manufacturing facility in Springfield, N.J.
Fusion Pharmaceuticals Inc., of Hamilton, Ontario, has established terms for its IPO and plans to raise up to $125 million by offering 8.4 million shares at a price range of $14 to $16. Its Fast-Clear linker technology platform attaches alpha particle emitting isotopes to targeting molecules to create radiopharmaceuticals for the treatment of cancer. The lead program, FPI-1434, is currently in a phase I study for solid tumors expressing insulin-like growth factor 1 receptor. It plans to list its shares on Nasdaq under the symbol FUSN.
IMV Inc., of Dartmouth, Nova Scotia, said it has filed a preliminary short form base shelf prospectus with relevant Canadian securities regulatory authorities and the SEC to replace its prior base shelf prospectus. The new filing will allow the company to offer up to $125 million of securities during the 25-month period that the shelf prospectus will be effective.
Inmed Pharmaceuticals Inc., of Vancouver, British Columbia, is conducting an IPO in the U.S. and plans to raise up to $12 million. It also plans to conduct a 1-for-33 share consolidation of its issued and outstanding common shares. The company, which is developing a pipeline of cannabinoid-based medications initially focused on the therapeutic benefits of cannabinol, plans to list its shares on Nasdaq under the symbol INM.
Inventiva SA, of Daix, France, which is developing oral small-molecule therapies for the treatment of nonalcoholic steatohepatitis, mucopolysaccharidoses, said it has filed to conduct a proposed IPO of its American depositary shares (ADSs) in the U.S., and a concurrent offering of its ordinary shares in certain jurisdictions outside of the U.S. The company has applied to list its ADSs on Nasdaq under the ticker symbol IVA.
Nkarta Inc., of South San Francisco, has filed to conduct an IPO and plans to raise up to $100 million. It is developing engineered natural killer cell therapies to treat cancer. In its filing, it reported that it had submitted an IND for NKX-101 for the treatment of relapsed or refractory acute myeloid leukemia and higher-risk myelodysplastic syndromes in May. It expects to initiate a broad clinical program for NKX-101 for blood cancers and solid tumors this year. The company had applied to list its shares on Nasdaq under the symbol NKTX.
Polypid Ltd., of Petah Tikva, Israel, has filed to raise $50 million in an IPO by selling 3.1 million shares at a price range of $15 to $17. The company’s lead candidate, D-PLEX100, is in a phase II trial for bone surgical site infections, and the first patient in that study was dosed in February. It plans to list on Nasdaq under the symbol PYPD.
Poseida Therapeutics Inc., of San Diego, which is developing CAR T-cell therapies, has filed to raise up to $115 million from an IPO. In May, it reported the first patient had been dosed in its phase I trial evaluating P-PSMA-101, its autologous CAR T therapeutic candidate, in metastatic castration-resistant prostate cancer. It plans to list its shares on Nasdaq under the symbol PSTX.
Zealand Pharma A/S, of Copenhagen, said as part of completion of a directed issue and private placement, it has increased its capital by DKK2,684,461 (US$405,317).